BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, September 24, 2023
Home » Blogs » BioWorld MedTech Perspectives » Is med-tech really ready for total transparency?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Is med-tech really ready for total transparency?

May 1, 2012
By Omar Ford
No Comments

Years ago at another publication, one of my former colleagues made one of the greatest rookie mistakes a person could make during their career. He triumphantly displayed how much money he was being paid to several reporters in the newsroom.

The pandemonium was classic. Many marched up to management and demanded salary adjustments, using this poor naïve writer's pay as a "negotiating" ground.

I wonder if something similar to this scenario will play out when the Physican Payment Sunshine Act will go into effect. I realize that med-tech said that it doesn't mind the transparency, but are companies considering the kind of backlash this will have from paid consultants, who now have a sense of what their competitors are getting paid?

I really didn't start thinking about this point until after I had a conversation with Michaeline Daboul president/CEO MMIS, a company that designs systems that enable organizations to manage and exchange data, earlier this month.

"When all this information gets published in a public online database and everybody from pro-publica to individuals start combing through this data, companies are going to have big PR nightmares," Daboul said in an April 15th interview with Medical Device Daily. "They're going to have customers who're going to be upset with them. You're going to have situations where you have customers that say, you didn't tell me you were going to tell the world that you bring us lunch every week."

While it might seem a bit simplistic, these kinds of issues can create a rift between med-tech firms and their clients, Daboul pointed out.

And I agree, whole-heartedly. It's going to be interesting when this hits the fan. But I wonder, med-tech, are you truly ready for total transparency?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing